Seres Therapeutics Newsroom

Seres Therapeutics to Participate in Piper Sandler Healthcare Conference

GlobeNewswireNov 22 20:00

Benign Growth For Seres Therapeutics, Inc. (NASDAQ:MCRB) Underpins Stock's 30% Plummet

Simply Wall StNov 15 20:08

Seres Therapeutics Price Target Maintained With a $10.00/Share by Canaccord Genuity

Dow JonesNov 15 00:20 · Ratings

Seres Therapeutics Is Maintained at Buy by Canaccord Genuity

Dow JonesNov 15 00:20 · Ratings

Promising Developments and Financial Stability Drive Buy Rating for Seres Therapeutics

TipRanksNov 14 20:26 · Ratings

Seres Therapeutics Reports Q3 2024 Results and Strategic Progress

TipRanksNov 14 12:03

Chardan Capital Maintains Buy on Seres Therapeutics, Maintains $1.25 Price Target

BenzingaNov 14 07:56 · Ratings

TD Cowen Maintains Seres Therapeutics(MCRB.US) With Buy Rating

Futu NewsNov 14 00:32 · Ratings

Seres Therapeutics (MCRB) Gets a Buy From TD Cowen

TipRanksNov 13 23:55 · Ratings

Seres Therapeutics, Inc. (MCRB) Q3 2024 Earnings Call Transcript Summary

Futu NewsNov 13 23:37 · Conference Call

Seres Therapeutics | 10-Q: Q3 2024 Earnings Report

SECNov 13 23:33 · Announcements

Seres Therapeutics, Inc. (MCRB) Q3 2024 Earnings Call Transcript

Earnings Call TranscriptsNov 13 23:28

Seres Therapeutics Faces Nasdaq Challenge Amid Trial Success

TipRanksNov 13 21:31

Seres Therapeutics | 8-K: SERES THERAPEUTICS REPORTS THIRD QUARTER 2024 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATES

SECNov 13 21:07

Seres Therapeutics GAAP EPS of -$0.33 Misses by $0.25

Seeking AlphaNov 13 20:05

Express News | Seres Therapeutics Inc: Co Expects to Fund Operations Into Q4 2025

BreakingsNov 13 20:01

Seres Therapeutics 3Q Net $88.8M >MCRB

Dow JonesNov 13 20:00

Express News | Seres Therapeutics Q3 Operating Income USD -29.17 Million

BreakingsNov 13 20:00

Earnings Scheduled For November 13, 2024

BenzingaNov 13 16:32

Seres Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Updates

Seres TherapeuticsNov 13 13:00